San Antonio's CTRC launches new clinical trial for brain cancer treatment

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor — thanks in part to new technology developed at the Cancer Therapy &Research Center at The University of Texas Health Science Center at San Antonio. The concept was developed by nuclear medicine physician William Phillips, biochemist Beth A. Goins and Ande Bao, a medical physicist and pharmaceutical chemist. All of the work took place in the School of Medicine at the Health…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Credit: Christine Daniloff/MIT A team of researchers from Brigham &Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to check for a mutation linked to glioma and implanted microparticles that slowly elute drug over the course of several days or even weeks to treat the brain cancer. Get the full story at our sister site, D...
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Brigham & Women's Hospital Massachusetts General Hospital Massachusetts Institute of Technology Source Type: news
PET scans with the radiotracer F-18 fluorothymidine (FLT) can help determine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET, MRI may predict pediatric brain tumor outcomes FDG-PET/CT beats FLT-PET/CT for differentiated thyroid cancer FLT-PET could help predict outcome in head and neck cancer JNM: FLT-PET aids prognosis of glioma patients FLT-PET helps predicts cancer therapy results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Abstract In recent years, we have witnessed a significant increase in the amount of studies using Mesenchymal Stem Cells (MSCs) for cancer therapy, mostly as vectors for drug or gene delivery strategies. This is because of their intrinsic capacity of homing into tumor niches. However, the interactions between MSCs themselves and tumor cells is not fully understood, with contradictory results frequently being observed regarding their effects on cancer cell invasion and proliferation. This poses an important question of safety in respect to the application of these cells. The source of the MSC population used, as we...
Source: Biochimie - Category: Biochemistry Authors: Tags: Biochimie Source Type: research
Authors: Sun S, Du G, Xue J, Ma J, Ge M, Wang H, Tian J Abstract Indoleamine 2,3-dioxygenase (IDO), which is highly expressed in human glioblastoma and involved in tumor immune escape and resistance to chemotherapy, is clinically correlated with tumor progression and poor clinical outcomes, and is a promising therapeutic target for glioblastoma. IDO inhibitors are marginally efficacious as single-agents; therefore, combination with other therapies holds promise for cancer therapy. The aim of this study was to investigate the anti-tumor effects and mechanisms of the IDO inhibitor PCC0208009 in combination with temoz...
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Tags: Int J Immunopathol Pharmacol Source Type: research
Authors: Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Namba H, Mori K, Tomiyama A Abstract Glioblastoma (GBM) still carries a poor prognosis due to the refractoriness against antitumor drugs. Temozolomide (TMZ), one of the few standard therapy drugs against GBM worldwide, has only limited effect due to acquired TMZ resistance of GBM. Therefore, development of novel therapeutic methods to overcome the TMZ resistance of GBM is urgent. The brain is the most cholesterol-rich organ in the human body, so modulation of cholesterol in tumor cells originating from the brain ...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
This issue of Neurologic Clinics is devoted to nervous system tumors as well as neurologic complications of cancer and cancer therapy. Since the last issue devoted to neuro-oncology 10 years ago, increased understanding of the molecular underpinnings of primary brain tumors has led to the addition of molecular parameters for the first time to the WHO classification of central nervous system tumors. Therefore, the first half of this issue focuses on the molecular pathogenesis of gliomas, the reasoning behind the recent changes in WHO classification, and their implications for management of adult and pediatric brain tumors.
Source: Neurologic Clinics - Category: Neurology Authors: Tags: Preface Source Type: research
CONCLUSION:   Tryptophan metabolism represents a metabolic node in glioblastoma and combining RT with IDO1 inhibition enhances therapeutic response by mitigating RT-induced immune suppression. PMID: 29691296 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractThe autonomic nervous system (ANS) is the main homeostatic regulatory system of the body. However, this widely distributed neural network can be easily affected by cancer and by the adverse events induced by cancer treatments. In this review, we have classified the ANS complications of cancer into two categories. The first includes direct cancer-related complications, such as primary ANS tumors (pheochromocytoma, paraganglioma or neuroblastoma), as well as autonomic manifestations induced by non-primary ANS tumors (primary brain tumors and metastases). The second comprises indirect ANS complications, which include ...
Source: Clinical Autonomic Research - Category: Research Source Type: research
We report here that such a treatment of PC1/3 KD macrophages drove to the overexpression of proteins mainly involved in cytoskeleton rearrangement. In support of this finding, we found that these cells exhibited a Ca2+ increase after Paclitaxel treatment. This is indicative of a possible depolymerization of microtubules and may therefore reflect an activation of inflammatory pathways in macrophages. In such a way, we found that PC1/3 KD macrophages displayed a repression of the anti-inflammatory pathway STAT3 and secreted more pro-inflammatory cytokines. Extracellular vesicles isolated from these PC1/3 KD cells inhibited g...
Source: Molecular and Cellular Proteomics : MCP - Category: Molecular Biology Authors: Tags: Mol Cell Proteomics Source Type: research
Publication date: Available online 3 March 2018 Source:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Author(s): Xin Yao Qiu, Dian Xing Hu, Wen-Qiang Chen, Ruo Qiao Chen, Shi Rui Qian, Chun Yang Li, Yuan Jun Li, Xin Xin Xiong, Di Liu, Feng Pan, Shang Bin Yu, Xiao Qian Chen Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor due to the lack of effective therapeutic drugs. Cancer therapy targeting programmed cell death protein 1 (PD-1) or programmed death ligand-1 (PD-L1) is of revolutionary. However, the role of intrinsic PD-L1, which determines immune-therapy outcomes, remains largel...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
More News: Biochemistry | Biotechnology | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Clinical Trials | Health | Health Management | Neurology | Nuclear Medicine | Physics | Science | Texas University